Current research

Check out the latest research on psilocybin’s impact on the following conditions:

  • Depression

  • PTSD

  • Addiction

  • Terminal illness-related anxiety

Current as of 2026

✳︎

Current as of 2026 ✳︎

52-Week follow-up confirms benefit following a single dose of psilocybin for MDD and TRD

Click Here to Learn More

Psilocybin produces substatial and sustained decrease in depression/anxiety in cancer patients

Click Here to Learn More

75% of veterans with treatment-resistent PTSD in remission at one-month follow-up. Treatment included 2 psilocybin sessions and 8 hrs of therapy.

Click Here to Learn More

30% of participants with Cocaine Use Disorder abstinant for 180 days after one dose of psilocybin, compared with 0% in the placebo group

Click Here to Learn More

Psilocybin can help reduce number of drinks per day and number of heavy drinking days in people with Alcohol Use Disorder

Click Here to Learn More

Keep an eye out: New VA Study focused on PTSD (2026-2030)

Click Here to Learn More

“There is ample evidence that, wisely administered, [PSYCHEDLICS] lessen the suffering caused by addiction, disease, and mental anguish.

James Fadiman, Psychedelic Researcher
BA, Harvard
Ph.D in Psychology, Stanford